A total of 29 companies entered the public market this past week, the most ever in a single week. The week’s 11 IPOs were joined by 15 SPACs and three direct listings. Notable new IPO filings included TPG-backed antivirus provider ...read more
Orphazyme, a Danish late-stage biotech developing protein therapies for rare neurodegenerative diseases, raised $84 million by offering 7.6 million ADS equivalents at $11, below the as-converted last close of its shares on the Nasdaq Copenhagen (ORPHA). At...read more
Updated Monday, 9/28.
11 IPOs and two direct listings are scheduled to go public in the week ahead. The diverse group includes three foreign tech issuers, two biotechs, two US tech unicorns, a sporting goods retailer, an avocado supplier, a medical...read more
Orphazyme, a Danish late-stage biotech developing protein therapies for rare neurodegenerative diseases, announced terms for its IPO on Monday. The Copenhagen, Denmark-based company plans to raise $100 million by offering 7.6 million ADSs at $13.13, the...read more
US IPO Weekly Recap: IPOs, SPACs, and direct listings, oh my!
A total of 29 companies entered the public market this past week, the most ever in a single week. The week’s 11 IPOs were joined by 15 SPACs and three direct listings. Notable new IPO filings included TPG-backed antivirus provider ...read more
Danish rare disease biotech Orphazyme prices US IPO at $11
Orphazyme, a Danish late-stage biotech developing protein therapies for rare neurodegenerative diseases, raised $84 million by offering 7.6 million ADS equivalents at $11, below the as-converted last close of its shares on the Nasdaq Copenhagen (ORPHA). At...read more
US IPO Week Ahead: Palantir and Asana direct-list in 11 IPO week with tech, sports, and avocados
Updated Monday, 9/28. 11 IPOs and two direct listings are scheduled to go public in the week ahead. The diverse group includes three foreign tech issuers, two biotechs, two US tech unicorns, a sporting goods retailer, an avocado supplier, a medical...read more
Danish rare disease biotech Orphazyme sets terms for $100 million US IPO
Orphazyme, a Danish late-stage biotech developing protein therapies for rare neurodegenerative diseases, announced terms for its IPO on Monday. The Copenhagen, Denmark-based company plans to raise $100 million by offering 7.6 million ADSs at $13.13, the...read more